|
Osmetech plc, the international healthcare diagnostics group will provide the following update during its Extraordinary General Meeting at 11:00am today:
During the first six months of 2006, the Group has continued to build on the strong sales growth achieved in 2005. Sales for the 6 month period ended 30 June 2006 are 36% ahead of the corresponding period in 2005.
The majority of sales relate to the Critical Care division where sales exceeded $8.6m, up by 34% on the corresponding period in 2005, with sales increasing in both human and veterinary markets.
As planned, in the first half of the year, Osmetech’s Molecular Diagnostics Division launched its FDA approved eSensor Cystic Fibrosis Carrier Detection test and eSensor 4800 DNA Detection instrument and OPTI TUBE product for use in the Roche LightCycler as a cost-effective and safe alternative to the Roche glass capillaries. Our OPTI GENE instrument and proprietary consumable system for the rapid detection of DNA and RNA targets will be launched with thrombophilia assays at the American Association of Clinical Chemists (AACC) Conference in Chicago later this month.
We are confident of further sales growth for the Group in the second half of the year. We expect our Critical Care division to report a record sales performance during the next six month period with a growing contribution from our new OPTI LION and OPTI R instruments and further strong sales growth of the VetStat product by our distribution partner, IDEXX, in the veterinary market. We also expect to report early commercial success with our new molecular diagnostics products as we start to build a significant presence in this rapidly growing market.
For further information:
Osmetech plc 0207 849 6027
James White, Chief Executive Officer
David Sandilands, Chief Financial Officer
Madano partnership 0207 593 4000
Matthew Moth
Mark Way
|
